



Edgar Filing: ARCA biopharma, Inc. - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Section 8 — Other Events

Item 8.01. Other Events.

On April 18, 2016, ARCA biopharma, Inc. (“ARCA”) provided a GENETIC-AF clinical trial update. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit<br>Number | Description  |
|-------------------|--|
| 99.1              | Press Release titled “ARCA biopharma Announces 7 <sup>th</sup> Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial” dated April 18, 2016. |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 18, 2016

ARCA biopharma, Inc.  
(Registrant)

By: /s/ Brian L. Selby  
Name: Brian L. Selby  
Title: Vice President, Finance and Chief Accounting Officer

---

INDEX TO EXHIBITS

| Exhibit<br>Number | Description  |
|-------------------|--|
| 99.1              | Press Release titled “ARCA biopharma Announces 7 <sup>th</sup> Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial” dated April 18, 2016. |